About BioPharma Credit PLC

About BioPharma Credit PLC

BioPharma Credit PLC (the “Company”, the “Fund”, or “BioPharma Credit”) provides investors with an opportunity to gain exposure to the fast-growing life sciences industry, through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. BioPharma Credit’s primary objective is to generate predictable income for shareholders over the long term.

BioPharma Credit will target an annual dividend yield of 7 per cent. (calculated by reference to the Issue Price), and a net total return on NAV of 8 to 9 per cent. per annum in the medium term.

Pharmakon Advisors, LP, the Fund’s investment manager (“Pharmakon” or the “Investment Manager”), was founded in 2009 and has committed US$9.8 billion across 57 transactions.  Drawing upon the expertise and successful track record of the Investment Manager, the fund enjoys access to its extensive, industry-focused knowledge and contacts to source, analyse and structure attractive investment opportunities.

Management & Board

Board of Directors

Harry Hyman

Chairman

Harry Hyman is the founder and Chair of Primary Health Properties PLC (“PHP”), a FTSE 250 Real Estate Investment Trust that specialises in the ownership of property leased on a long-term basis to healthcare providers. After graduating from Christ’s College Cambridge, Mr Hyman qualified as a chartered accountant with Price Waterhouse. In 1983 he joined Baltic PLC where he was deputy managing director, finance director and company secretary. He left to establish PHP and Nexus in February 1994. Mr Hyman is the founder of The International Opera Awards. He has been a non-executive director of a number of listed investment trusts.

Duncan Budge

Director

Duncan Budge is chairman of Dunedin Enterprise Investment Trust PLC and Artemis Alpha Trust PLC, and a nonexecutive director of Lowland Investment Company PLC and Asset Value Investors Limited. He was previously a director of Menhaden Resource Efficiency PLC from 2014 to 2023, J. Rothschild Capital Management from 1988 to 2012 and a director and chief operating officer of RIT Capital Partners PLC from 1995 to 2011. After graduating from the University of Oxford, he spent six years with Lazard Brothers.

Colin Bond

Director

Colin Bond has been chief financial officer of the pharmaceutical company Sandoz AG since May 2022. He was previously chief financial officer of Vifor Pharma from 2016 to 2022 and he was the chief financial officer of Evotec AG from 2010 to 2016. During his early career, he worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PricewaterhouseCoopers LLP, respectively. He holds a university degree in Pharmacy from the University of Aston (Birmingham) and an M.B.A. degree from London Business School. He is a fellow of the Institute of Chartered Accountants in England and Wales and a member of the Royal Pharmaceutical Society. Mr Bond is a citizen of Great Britain and Switzerland.

Stephanie Léouzon

Director

Stephanie Léouzon has had over 30 years experience as a Health Care Investment Banker, and is a Managing Director in Health Care Investment Banking at Stifel. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion. Mrs Leouzon joined Torreya (a Stifel company) in 2011. Previously, she was a Managing Director and Senior Adviser at Credit Suisse in London. She has also worked at Salomon Brothers, as a Director of healthcare investment banking, and as a Vice President in the investment banking divisions of JP Morgan and Lehman Brothers in New York. She was previously a non-executive director of Innmunovaccine Inc and Endotis Pharma SA.

Rolf Soderstrom

Director

Rolf Soderstrom is an Executive Partner and former Chief Financial Officer at Syncona Investment Management Limited and External Independent Director of Nxera Pharma, which is listed on the Tokyo Stock Exchange. Previous roles include Chief Financial Officer of BTG PLC between 2008 and 2018 where he helped implement and execute a transformational growth strategy culminating in a sale to Boston Scientific for $4.2bn. Prior to this he was Chief Financial Officer at Protherics PLC and held senior finance roles in Cobham PLC, Cable & Wireless PLC and PwC. He received a BA honours degree in History from University College London and is a member of the Institute of Chartered Accountants of England and Wales.

Sapna Shah

Director

Sapna Shah has over 20 years of investment banking experience advising international companies, including listed REITs and investment companies, on mergers and acquisitions, IPOs and equity capital market transactions. Ms Shah is a nonexecutive director of Supermarket Income REIT PLC and chair of its management engagement committee, a non-executive director of BlackRock Greater Europe Investment Trust PLC, and a non-executive director and member of the remuneration committee of The Association of Investment Companies (“AIC”). She is a Senior Adviser at Panmure Gordon Limited and prior to this held senior investment banking roles at UBS AG, Oriel Securities (now Stifel Nicolaus Europe) and Cenkos Securities. She has previously served on the advisory committee for a private solar energy company.

---

Investment Team

Pedro Gonzalez de Cosio

Investment Manager

Mr. Gonzalez de Cosio is a Principal, co-founder and Chief Executive Officer of the Investment Manager, and manages the Company’s portfolio. During the 14 years prior to founding the Investment Manager, Mr. Gonzalez de Cosio held various positions in the structured finance divisions of Deutsche Bank and JP Morgan in New York, where he was responsible for structuring various forms of collateralized financings and derivatives for U.S. and international clients, including several years covering clients in the life sciences industries. Mr. Gonzalez de Cosio’s prior experience also includes various positions in the investment banking division of Nomura Securities in New York, the leasing division of Société Générale in Paris, and coordinating the issuance of external debt for the Mexican Ministry of Finance. Mr. Gonzalez de Cosio earned a B.A. degree (Summa Cum Laude) in Business Administration from the University of San Diego and an M.B.A. from INSEAD in Fontainebleau, France.

Pablo Legorreta

Investment Manager

Mr. Legorreta is Founder and Chief Executive Officer of Royalty Pharma and a Principal and co-founder of the Investment Manager, providing advisory oversight. Founded in 1996, Royalty Pharma is the industry leader in pharmaceutical royalties. Prior to founding Royalty Pharma, Mr. Legorreta had a ten-year career in investment banking with Lazard Frères in Paris and New York. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana (Mexico City), Mexico.

Martin Friedman

Investment Manager

Mr. Friedman is a Principal of the Investment Manager, having joined in 2011. Prior to joining the Investment Manager, Mr. Friedman has worked in various positions in the Health Care Finance industry most recently as the Co-Head of Life Sciences banking at Bank of America/Merrill Lynch for 3 years. He has worked very closely with both large cap and emerging Pharma, Biotech, Specialty Pharma, Device and Diagnostic companies having advised on M&A transactions and raised equity and debt capital. Mr. Friedman’s prior experience also includes 12 years at JP Morgan including 4 years at JP Morgan Partners and several years as the Head of M&A and Collaborations at Novartis AG based in Switzerland. Mr. Friedman earned a B.A. degree in English and History from Columbia College and an M.B.A. (Honors) in Finance and Accounting from Columbia Business School.